Desmopressin EP Impurity A is a reference impurity standard reflecting a closely related structural variant of desmopressin. Changes in residue connectivity or oxidation state alter chromatographic and spectrometric signatures. Researchers use it to verify analytical selectivity and quantify trace levels in formulations. Applications include impurity profiling, stability-indicating method development, and peptide-process optimization.
CAT No: R2743
Synonyms/Alias:[5-L-aspartic acid]desmopressin;2-((4R,7S,10S,13S,16S)-4-((S)-2-(((R)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-7-yl)acetic acid
Desmopressin EP Impurity A, a structurally related analogue of the synthetic peptide desmopressin, represents a significant reference standard in the field of pharmaceutical research and quality control. Characterized by its close resemblance to the parent compound, this impurity is critical for the comprehensive evaluation of desmopressin-based formulations. Its unique peptide sequence and physicochemical properties enable researchers to distinguish between the active pharmaceutical ingredient and related substances, ensuring product integrity and safety. As a result, Desmopressin EP Impurity A serves as an indispensable tool for method development, validation, and impurity profiling, supporting robust analytical workflows in both academic and industrial settings.
Pharmaceutical analytical method development: In the context of pharmaceutical research, Desmopressin EP Impurity A is widely utilized for the development and validation of chromatographic and spectrometric methods. By incorporating this impurity into analytical protocols, laboratories can accurately assess the specificity, sensitivity, and reproducibility of their assays. The presence of such structurally related impurities challenges the selectivity of analytical methods, prompting the optimization of separation parameters and detection techniques. This process not only enhances the reliability of desmopressin quantification but also aids in the identification and quantification of trace-level impurities, which is essential for maintaining the quality of pharmaceutical products.
Impurity profiling in drug substance and product: As a well-characterized reference compound, Desmopressin EP Impurity A plays a pivotal role in impurity profiling studies for both active pharmaceutical ingredients and finished dosage forms. Its inclusion in impurity panels allows researchers to monitor the formation, degradation, and persistence of related substances throughout the manufacturing and storage processes. By comparing retention times, mass spectra, and other analytical signatures, scientists can trace the origins of impurities and implement effective control strategies. This capability is especially important for ensuring that desmopressin drug products meet stringent quality requirements and remain safe for therapeutic use.
Stability studies and forced degradation investigations: The application of Desmopressin EP Impurity A extends to stability-indicating studies, where it serves as a marker for the evaluation of desmopressin's degradation pathways. In forced degradation experiments, the impurity is used to simulate potential breakdown products that may arise under stress conditions such as heat, light, or oxidative environments. By tracking the appearance and concentration of this impurity over time, researchers gain valuable insights into the chemical stability of desmopressin formulations. These findings inform the development of robust storage guidelines and shelf-life predictions, ultimately supporting the long-term efficacy of peptide-based pharmaceuticals.
Process development and optimization: During the synthesis and purification of desmopressin, Desmopressin EP Impurity A is employed as a benchmark to evaluate process efficiency and impurity clearance. Analytical monitoring of its levels at various stages of production allows chemists to optimize reaction conditions, select appropriate purification techniques, and minimize the carryover of related substances. This proactive approach to process control not only improves yield and purity but also streamlines regulatory documentation by providing comprehensive impurity profiles for each batch.
Peptide research and structural elucidation: Beyond its applications in pharmaceutical quality assurance, Desmopressin EP Impurity A serves as a valuable reference in peptide research and structural analysis. Its defined sequence and known properties make it an ideal standard for mass spectrometry, nuclear magnetic resonance, and other advanced analytical techniques. By comparing experimental data with those obtained from the impurity, researchers can confirm the identity of unknown peptides, elucidate fragmentation patterns, and investigate structure-activity relationships. These insights contribute to a deeper understanding of peptide chemistry, supporting the design of novel analogues and the advancement of therapeutic innovation.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More